Non-small cell lung cancer NSCLC
Genes that are candidates in both lung adenocarcinoma and lung squamous cell carcinoma, the two non-small cell lung cancer types profiled by TCGA. 826 genes qualify in both; 442 of them (54%) have supporting plasma Cell-free RNA (cfRNA)RNA fragments that circulate in blood plasma outside cells. Most come from blood cells; a small share comes from other tissues, including tumors. evidence, and 379 are non-coding genes the plasma sources cannot check.
An overlap, not a pooled analysis. Each gene passed every step separately in LUAD and in LUSC, against that cancer type’s own samples. Large-cell carcinoma and other rarer NSCLC types are not in TCGA.
Candidates in each cancer type
Plasma evidence for the 826 shared genes
Samples compared, separately for each type
| Cancer type | Tumors | Normal | Candidates |
|---|---|---|---|
| Lung adenocarcinoma (LUAD)vs normal lung | 513 | 347 | 1,364 |
| Lung squamous cell carcinoma (LUSC)vs normal lung | 498 | 338 | 2,156 |
Both are also compared with the same 337 GTEx whole-blood samples.
Shared candidates
Ranked by the weaker of each gene’s two Priority scoreThe mean of the two AUCs, plus 0.05 for each plasma source that supports the gene (at most 0.15). Candidates are ranked by this score., so a gene ranks high only if it is strong in both cancer types. Select a gene to see it across every cancer type.
Caveats for NSCLC
- Large-cell carcinoma and other rarer NSCLC types are not in TCGA.
- The blood comparison sets TCGA tumors against GTEx blood. Study and biology cannot be separated there, which is why genes made by blood immune cells are removed as well.